A forum for researchers, students and applicants in the field of cyclodextrin technology
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
Bacteria are single-celled prokaryotic microorganisms, that means they do not have a true nucleus, mitochondria, or any other membrane-bound organelle
Gilead Sciences’ SBECD-enabled remdesivir (GS-5734) was highlighted in the New England Journal of Medicine last week for treating the first
